Dr. Noel W. Clarke presented “Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: metastatic prostate cancer, bone targeted agents, Denosumab, Bisphosphonates, Radium-223, TRAPEZE, ALSYMPCA
How to cite: Clarke, Noel. “Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2024. https://dev.grandroundsinurology.com/bone-targeted-agents-metastatic-prostate-cancer-denosumab-bisphosphonates-radium-223
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Noel Clarke has been a consultant urologist at Salford Royal Hospital and The Christie, Manchester, since 1993, and was made Honorary Professor of Urologic Oncology by Manchester University in 1997. His specialist expertise is in prostate, bladder, renal, and testis cancer, and in complex pelvic and retroperitoneal malignancy. Professor Clarke is a former Director of Urology at both Salford and The Christie, and the former Chair of the Manchester and Cheshire Clinical Study Group (CSG) and the National Cancer Research Institute Prostate CSG. He is currently Director of Manchester University’s Genitourinary Cancer Research Group, a member of the Department of Health and National Cancer Research Network Prostate Cancer Advisory Boards, Chair of the European Organisation for Research and Treatment of Cancer Prostate Disease Group, and author of over 150 publications, including eight book chapters on urological cancer. Professor Clarke has planned and managed multiple trials in the UK and Europe and has given various national and international guest lectures on urologic cancer.
